Literature DB >> 23252691

Investigation of 20 non-HLA (human leucocyte antigen) psoriasis susceptibility loci in Chinese patients with psoriatic arthritis and psoriasis vulgaris.

Q Yang1, H Liu, L Qu, X Fu, Y Yu, G Yu, H Tian, Y Yu, D Sun, J Peng, F Bao, C Yuan, N Lu, J Li, Y Zhang, F Zhang.   

Abstract

BACKGROUND: Recently, a number of non-HLA (human leucocyte antigen) psoriasis genetic susceptibility loci have been identified through genome-wide association studies, but data on their association with psoriatic arthritis (PsA) are lacking.
OBJECTIVES: To investigate recently identified psoriasis susceptibility loci in a cohort of Chinese patients with PsA, psoriasis vulgaris (PsV) and healthy controls.
METHODS: Twenty single-nucleotide polymorphisms (SNPs) from 20 loci were selected for genotyping in 379 patients with PsA, 595 patients with PsV and 1181 healthy controls using the MassARRAY platform (Sequenom, San Diego, CA, U.S.A.). Data handling, quality control and association were performed using PLINK software, v. 1.07. The Cochran-Armitage trend test was used to test the genotype-phenotype association.
RESULTS: PsA showed a significant association with markers at TNIP1 (rs17728338, P = 2.20 × 10(-8)), IL28RA (rs4649203, P = 5.04 × 10(-6)), IL12B (rs2082412, P = 3.82 × 10(-5)), ERAP1 (rs27524, P = 1.25 × 10(-3)), PTTG1 (rs2431697, P = 1.22 × 10(-3)) and GJB2 (rs3751385, P = 1.48 × 10(-3)) when compared with the control group. In PsV a significant association was found for IL28RA (rs4649203, P = 9.53 × 10(-7)), TNIP1 (rs17728338, P = 1.21 × 10(-4)) and ERAP1 (rs27524, P = 1.17 × 10(-3)). The allele frequencies were not statistically different between PsA and PsV except for SNPs at IL12B and ZNF816A with a nominal P-value of 0.04 and 0·01, respectively.
CONCLUSIONS: This study provides evidence for the involvement of ERAP1, IL28RA, GJB2 and PTTG1 loci in PsA susceptibility and confirmed the previously reported association with PsA and PsV. These results support the hypothesis that genetic aetiology of psoriasis is the same in both PsA and PsV and also support the higher genetic component of PsA than PsV.
© 2012 The Authors. BJD © 2012 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23252691     DOI: 10.1111/bjd.12142

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  20 in total

1.  Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture.

Authors:  Philip E Stuart; Rajan P Nair; Lam C Tsoi; Trilokraj Tejasvi; Sayantan Das; Hyun Min Kang; Eva Ellinghaus; Vinod Chandran; Kristina Callis-Duffin; Robert Ike; Yanming Li; Xiaoquan Wen; Charlotta Enerbäck; Johann E Gudjonsson; Sulev Kõks; Külli Kingo; Tõnu Esko; Ulrich Mrowietz; Andre Reis; H Erich Wichmann; Christian Gieger; Per Hoffmann; Markus M Nöthen; Juliane Winkelmann; Manfred Kunz; Elvia G Moreta; Philip J Mease; Christopher T Ritchlin; Anne M Bowcock; Gerald G Krueger; Henry W Lim; Stephan Weidinger; Michael Weichenthal; John J Voorhees; Proton Rahman; Peter K Gregersen; Andre Franke; Dafna D Gladman; Gonçalo R Abecasis; James T Elder
Journal:  Am J Hum Genet       Date:  2015-11-28       Impact factor: 11.025

2.  Association of TNFRSF1A and IFNLR1 Gene Polymorphisms with the Risk of Developing Breast Cancer and Clinical Pathologic Features.

Authors:  Leili Daiane Hausmann; Bibiana Sgorla de Almeida; Ilíada Rainha de Souza; Manuela Nunes Drehmer; Braulio Leal Fernandes; Renato Salerno Wilkens; Daniella Serafin Couto Vieira; Sara Emelie Lofgren; Juliana Dal-Ri Lindenau; Guilherme de Toledo E Silva; Yara Costa Netto Muniz
Journal:  Biochem Genet       Date:  2021-03-22       Impact factor: 1.890

Review 3.  Immune diseases caused by mutations in kinases and components of the ubiquitin system.

Authors:  Philip Cohen
Journal:  Nat Immunol       Date:  2014-06       Impact factor: 25.606

4.  Single nucleotide polymorphisms of the GJB2 and GJB6 genes are associated with autosomal recessive nonsyndromic hearing loss.

Authors:  Ana Paula Grillo; Flávia Marcorin de Oliveira; Gabriela Queila de Carvalho; Ruan Felipe Vieira Medrano; Sueli Matilde da Silva-Costa; Edi Lúcia Sartorato; Camila Andréa de Oliveira
Journal:  Biomed Res Int       Date:  2015-05-17       Impact factor: 3.411

Review 5.  The TLR and IL-1 signalling network at a glance.

Authors:  Philip Cohen
Journal:  J Cell Sci       Date:  2014-05-14       Impact factor: 5.285

Review 6.  Clinical, laboratory, and genetic markers for the development or presence of psoriatic arthritis in psoriasis patients: a systematic review.

Authors:  Michelle L M Mulder; Tamara W van Hal; Mark H Wenink; Hans J P M Koenen; Frank H J van den Hoogen; Elke M G J de Jong; Juul M P A van den Reek; Johanna E Vriezekolk
Journal:  Arthritis Res Ther       Date:  2021-06-14       Impact factor: 5.156

7.  Common MIR146A Polymorphisms in Chinese Ankylosing Spondylitis Subjects and Controls.

Authors:  Zhenmin Niu; Jiucun Wang; Hejian Zou; Chengde Yang; Wei Huang; Li Jin
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

8.  Are pre-miR-146a and PTTG1 associated with papillary thyroid cancer?

Authors:  Marco Marino; Valentina Cirello; Valentina Gnarini; Carla Colombo; Elisa Pignatti; Livio Casarini; Chiara Diazzi; Vincenzo Rochira; Katia Cioni; Bruno Madeo; Cesare Carani; Manuela Simoni; Laura Fugazzola
Journal:  Endocr Connect       Date:  2013-10-22       Impact factor: 3.335

9.  Evaluation of Psoriasis Genetic Risk Based on Five Susceptibility Markers in a Population from Northern Poland.

Authors:  Marta Stawczyk-Macieja; Krzysztof Rębała; Aneta Szczerkowska-Dobosz; Joanna Wysocka; Lidia Cybulska; Ewa Kapińska; Agnieszka Haraś; Paulina Miniszewska; Roman Nowicki
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

Review 10.  Molecular control of the NEMO family of ubiquitin-binding proteins.

Authors:  Kristopher Clark; Sambit Nanda; Philip Cohen
Journal:  Nat Rev Mol Cell Biol       Date:  2013-08-29       Impact factor: 94.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.